Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STI-0529
- Development stage
- Discontinued
- Lead developer
- Sublimity Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
STI-0529 (also known as CyCol) is an oral, colon-targeted formulation of cyclosporine developed by Sublimity Therapeutics. It utilizes the proprietary SmPill delivery technology, which consists of minispheres designed to release the active ingredient specifically in the colon. This localized delivery approach aims to treat moderate to severe ulcerative colitis by providing high concentrations of cyclosporine at the site of inflammation while minimizing systemic exposure and the associated toxicities, such as nephrotoxicity and hypertension. Cyclosporine acts as a calcineurin inhibitor, suppressing T-cell activation and the subsequent production of pro-inflammatory cytokines.
- Brand names
- CyCol
- Other names
- CyCol
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)MPTP (Mitochondrial permeability transition pore)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on STI-0529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STI-0529.